Alkem Laboratories Share Price

Alkem Laboratories Share Price

NSE: ALKEM
|
Pharmaceuticals
|
S Cap
â‚ą 5,300.00
-â‚ą29.50 (-0.55%)
1D
Last updated 01 Sep, 2026, 15:29 IST

Alkem Laboratories Share Price Today

As of 2 Sep 2026, Alkem Laboratories share price is â‚ą5,300.00. The stock opened at â‚ą5,329.50, compared to its previous close of â‚ą5,329.50. During today's trading session, Alkem Laboratories share price moved in the range of â‚ą5,277.00 to â‚ą5,358.00, with an average price of â‚ą5,317.50 for the day. Looking at its last 52-week, the stock has touched a low of â‚ą5,075.00 and a high of â‚ą5,933.50. On the performance front, Alkem Laboratories share price has declined by 6.02% over the last six months and is down 0.01% on a year-on-year basis.

â‚ą5,277.00
0.55% down today
â‚ą5,358.00
1D LOW
1D HIGH

Alkem Laboratories Returns Calculator

Circuit
L
H
â‚ą5,140.00
â‚ą5,457.00
52-week
L
H
â‚ą5,075.00
â‚ą5,933.50

About Alkem Laboratories

Alkem Laboratories Share Price
ISIN
INE540L01014
Sector Market Cap
â‚ą 64,007.9 Cr

Alkem Laboratories Ltd. is an India-based pharmaceutical company engaged in the development, manufacturing, and sale of pharmaceutical products. The Company operates in a single business segment-Pharmaceuticals. It produces branded generics, generic drugs, active pharmaceutical ingredients (APIs), and nutraceuticals, which it markets in India and international markets. It has a portfolio of approximately 800 brands in India and maintains a presence in over 40 international markets, with the United States being its key focus market. Its offerings include therapies, prescription (Rx) products, and Alkem generics. Its therapy offerings cover multiple medical fields, including anti-infectives, anti-osteoporosis, cardiology, neurology, dermatology, diabetology, gastroenterology, gynecology, oncology, ophthalmology, respiratory care, rheumatology, and urology. The Company’s subsidiaries include Ascend Laboratories (Pty) Ltd, Pharmacor Pty Limited, Alkem Laboratories Corporation, and others.

Alkem Laboratories Financial Highlights

  • Revenue: Alkem Laboratories reported revenue of â‚ą15,295.62 crore in FY26 vs â‚ą13,458.26 crore in FY25. It showed an increase of 13.65% on a yearly basis.
  • Operating Profit: Alkem Laboratories reported an operating profit of â‚ą2,870.89 crore in FY26 vs â‚ą2,527.03 crore in FY25. It showed an increase of 13.61% on a year-on-year basis.
  • Net Profit: Alkem Laboratories reported a net profit of â‚ą2,353.13 crore in FY26 vs â‚ą2,216.00 crore in FY25. It showed an increase of 6.19% on a yearly basis.

Alkem Laboratories Quarterly Result Highlights

  • Alkem Laboratories reported revenue of â‚ą3,892.90 crore in Jun 2026, compared with â‚ą3,803.39 crore in Mar 2026, representing an increase of 2.35% on a quarter-on-quarter (QoQ) basis.
  • Alkem Laboratories reported an operating profit of â‚ą771.99 crore in Jun 2026, compared with â‚ą422.85 crore in Mar 2026, representing an increase of 82.57% on a quarter-on-quarter (QoQ) basis.
  • Alkem Laboratories reported a profit of â‚ą521.49 crore in Jun 2026, compared with â‚ą251.68 crore in Mar 2026, reflecting an increase of 107.20% on a QoQ basis.
  • The earnings per share (EPS) of Alkem Laboratories stood at â‚ą192.51 during Jun 2026.
Know more
Promoters
49.70%
FII
10.42%
Other DII
5.93%
Retail and other
17.25%
Mutual funds
16.71%
Foreign institutions - FII
FII shareholding by period
Sep 20259.48%
Dec 20259.97%
Mar 202610.16%
Jun 202610.42%
Mkt Cap Cr
64,007.90
P/E
29.04
P/B
4.63
ROE
16.66%
D/E
0.04
ROCE
18.61%
Div. Yield
0.99%
EPS(TTM)
182.76
Turnover
0.58
EV/EBITDA
18.68
Net Margin
23.55%
Op. Margin
30.27%
ROA
10.57%
Quick Ratio
2.26
Curr. Ratio
3.57
Based on fundamentals, this stock's
Step 1 of 5
Performance
Very Poor
Alkem Lab has not beaten FD return of 7%
Step 1 of 5
Valuation
Overvalued
Alkem Lab appears overvalued compared to its peers
Step 5 of 5
Earnings
Excellent
Alkem Lab revenue, operating profit and net profit are growing
Peer Comparison
Peer comparison — key ratios
NameMkt Cap CrP/EP/BROED/EROCEBook ValueDiv. YieldTurnoverEPS(TTM)
Sun Pharmaceutical Industries4,69,310.0038.735.6213.74%0.6117.33%93.240.82%0.4810.90
Divis Laboratories2,45,426.0083.9114.6415.32%0.0019.56%629.490.32%0.5598.19
Torrent Pharmaceuticals1,89,347.0087.8322.5225.49%1.6913.85%222.760.68%0.4958.70
Zydus Lifesciences1,15,920.0025.284.2818.59%0.3117.35%237.300.09%0.3335.38
Cipla1,14,393.0034.093.3211.27%0.0014.95%423.360.92%0.4543.52
Laurus Labs1,03,038.0094.5019.4416.77%0.4016.14%97.200.10%0.6713.72
Lupin99,592.5017.944.4423.76%0.0424.88%659.000.83%0.57129.18
Mankind Pharma99,077.7047.926.0811.74%0.3413.13%397.020.04%0.4449.37
Dr. Reddy's Laboratories97,240.2030.552.5511.07%0.1812.54%377.950.68%0.4138.68
Aurobindo Pharma97,238.9026.212.579.25%0.1911.76%394.820.24%0.3841.58

Alkem Laboratories Financials

Full statement

Income Statement · Consolidated

Income Statement · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenueâ‚ą14,712.27â‚ą12,964.52â‚ą12,667.58â‚ą11,599.26
Other Incomeâ‚ą583.35â‚ą493.74â‚ą310.84â‚ą216.08
Total Revenueâ‚ą15,295.62â‚ą13,458.26â‚ą12,978.42â‚ą11,815.34
Total Expensesâ‚ą12,249.90â‚ą10,931.23â‚ą10,833.80â‚ą10,407.59
Profit Before Taxâ‚ą2,870.89â‚ą2,527.03â‚ą2,023.13â‚ą1,304.77
Taxâ‚ą517.76â‚ą311.03â‚ą211.67â‚ą297.96
Profit After Taxâ‚ą2,353.13â‚ą2,216.00â‚ą1,811.46â‚ą1,006.81
EPS - Basicâ‚ą192.51â‚ą181.11â‚ą150.19â‚ą82.31
EPS - Dilutedâ‚ą192.51â‚ą181.11â‚ą150.19â‚ą82.31

Cash Flow · Consolidated

Cash Flow · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before taxâ‚ą2,870.89â‚ą2,527.03â‚ą2,023.13â‚ą1,304.77
Income before WC changesâ‚ą3,007.22â‚ą2,630.83â‚ą2,406.70â‚ą1,629.12
Change in Assets-â‚ą663.72-â‚ą454.79-â‚ą430.50â‚ą261.69
Change in Liabilitiesâ‚ą248.55â‚ą240.82â‚ą378.81â‚ą65.08
Change in WC-â‚ą415.17-â‚ą213.97-â‚ą51.69â‚ą326.77
Cash flow from Operationsâ‚ą1,963.03â‚ą1,912.84â‚ą1,948.07â‚ą1,682.50
Cash flow from Investing-â‚ą1,667.21-â‚ą1,298.76-â‚ą1,008.50â‚ą112.84
Cash flow from Financing-â‚ą503.40-â‚ą810.99-â‚ą1,145.01-â‚ą1,760.82
Total Cash Flow-â‚ą207.58-â‚ą196.91-â‚ą205.44â‚ą34.52
Cash (Start of the year)-â‚ą120.09â‚ą66.31â‚ą273.80â‚ą232.18
Cash (End of the year)-â‚ą342.13-â‚ą120.09â‚ą66.31â‚ą273.80

Balance Sheet · Consolidated

Balance Sheet · Consolidated — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assetsâ‚ą8,662.45â‚ą6,879.91â‚ą5,163.32â‚ą5,026.95
Current Assetsâ‚ą12,210.52â‚ą10,811.19â‚ą10,411.58â‚ą8,729.70
Total Assetsâ‚ą20,872.97â‚ą17,691.10â‚ą15,574.90â‚ą13,756.65
Current Liabilitiesâ‚ą4,782.70â‚ą3,960.67â‚ą3,994.55â‚ą3,707.15
Net Current Assetâ‚ą7,427.82â‚ą6,850.52â‚ą6,417.03â‚ą5,022.55
Non-Current Liabilitiesâ‚ą1,741.34â‚ą1,296.80â‚ą865.95â‚ą614.50
Equity Capitalâ‚ą14,348.93â‚ą12,433.63â‚ą10,714.40â‚ą9,435.00
Total Equity & Liabilitiesâ‚ą20,872.97â‚ą17,691.10â‚ą15,574.90â‚ą13,756.65

Income Statement · Standalone

Income Statement · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Revenueâ‚ą9,663.91â‚ą8,813.44â‚ą7,963.85â‚ą9,054.55
Other Incomeâ‚ą555.17â‚ą507.06â‚ą305.99â‚ą266.29
Total Revenueâ‚ą10,219.08â‚ą9,320.50â‚ą8,269.84â‚ą9,320.84
Total Expensesâ‚ą7,553.37â‚ą7,016.96â‚ą6,611.88â‚ą7,993.85
Profit Before Taxâ‚ą2,522.62â‚ą2,303.54â‚ą1,594.13â‚ą1,326.99
Taxâ‚ą337.50â‚ą213.82â‚ą33.62â‚ą192.52
Profit After Taxâ‚ą2,185.12â‚ą2,089.72â‚ą1,560.51â‚ą1,134.47
EPS - Basicâ‚ą190.87â‚ą190.77â‚ą146.13â‚ą94.88
EPS - Dilutedâ‚ą190.87â‚ą190.77â‚ą146.13â‚ą94.88

Cash Flow · Standalone

Cash Flow · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Profit before taxâ‚ą2,671.67â‚ą2,597.39â‚ą1,881.03â‚ą1,326.99
Income before WC changesâ‚ą2,606.70â‚ą2,546.05â‚ą2,092.77â‚ą1,455.88
Change in Assets-â‚ą250.29-â‚ą179.20-â‚ą238.27â‚ą169.14
Change in Liabilitiesâ‚ą94.19â‚ą219.19â‚ą184.89â‚ą36.56
Change in WC-â‚ą156.10â‚ą39.99-â‚ą53.38â‚ą205.70
Cash flow from Operationsâ‚ą1,969.12â‚ą2,189.41â‚ą1,686.56â‚ą1,437.42
Cash flow from Investing-â‚ą1,461.25-â‚ą1,007.41-â‚ą865.60â‚ą197.04
Cash flow from Financing-â‚ą672.82-â‚ą1,036.89-â‚ą959.04-â‚ą1,711.27
Total Cash Flow-â‚ą164.95â‚ą145.11-â‚ą138.08-â‚ą76.81
Cash (Start of the year)â‚ą12.04-â‚ą133.07â‚ą5.01â‚ą81.82
Cash (End of the year)-â‚ą152.91â‚ą12.04-â‚ą133.07â‚ą5.01

Balance Sheet · Standalone

Balance Sheet · Standalone — all values in INR Crore
ParticularsMar 2026Mar 2025Mar 2024Mar 2023
Non-Current Assetsâ‚ą9,431.01â‚ą8,241.60â‚ą5,997.72â‚ą5,959.01
Current Assetsâ‚ą7,830.12â‚ą7,354.00â‚ą8,040.08â‚ą6,772.21
Total Assetsâ‚ą17,261.13â‚ą15,595.60â‚ą14,037.80â‚ą12,731.22
Current Liabilitiesâ‚ą2,746.81â‚ą2,543.44â‚ą3,106.40â‚ą3,044.83
Net Current Assetâ‚ą5,083.31â‚ą4,810.56â‚ą4,933.68â‚ą3,727.38
Non-Current Liabilitiesâ‚ą515.56â‚ą730.33â‚ą376.79â‚ą336.54
Equity Capitalâ‚ą13,998.76â‚ą12,321.83â‚ą10,554.61â‚ą9,349.85
Total Equity & Liabilitiesâ‚ą17,261.13â‚ą15,595.60â‚ą14,037.80â‚ą12,731.22
* All values are in INR Crore
Qty
Bid
0
0
0
0
0
0
0
0
0
0
Ask
Qty
5300
11
0
0
0
0
0
0
0
0
Bid Total: 0
Ask Total: 11
Buy orders: 0%
Sell orders: 100%
Bearish
2
Neutral
5
Bullish
1
Slightly Bearish
by SEBI experts
Expert Pick
EXPPICK
Stop-loss
Entry price
Target
Indicator
Value
Verdict
RSI (14)
39.44
Neutral
ATR (14)
109.5
Neutral
STOCH(9,6)
16.88
Bullish
STOCH RSI (14)
38.42
Neutral
ADX(9)
38.39
Bearish
UO(9)
46.27
Neutral
ROC(12)
-2.2
Bearish
WillR(14)
-57.02
Neutral
Period
Simple value
Exponential vaue
5D
5321.6
5327.93
10D
5350.85
5357.97
20D
5434.75
5417.85
50D
5536.92
5478.13
100D
5482.13
5492.34
Volume trend — traded volume by day
1 Sep0L
31 Aug1L
28 Aug2L
27 Aug1L
26 Aug0L
Average1L
Compare against other stocks
Alkem Laboratories Share Price
Alkem Laboratories
Pharmaceuticals
Add Stock
Add Another

Alkem Laboratories Share Price FAQs